Oncolytics Biotech Inc.
1167 Kensington Crescent NW
Suite 210
Calgary,
AB T2N 1X7
Canada - Map
Phone: 403-670-7377
Fax: 403-283-0508
Website: http://www.oncolyticsbiotech.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | N/A |
|
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada. Key Statistics
| |
| | Pay | Exercised | Dr. Bradley G. Thompson Ph.D.,
Exec. Chairman, Chief Exec. Officer and Pres | 582.00K | 0.00 | Mr. Kirk J. Look ,
Chief Financial Officer and Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. | 45.00K | 0.00 | Dr. Matthew C. Coffey Ph.D.,
Chief Operating Officer and Director | 400.00K | 0.00 | Dr. George M. Gill M.D.,
Chief Safety Officer and Sr. VP of Clinical & Regulatory Affairs | 336.00K | 0.00 | Dr. Alan J. Tuchman M.D.,
66
Chief Medical Officer and Sr. VP of Clinical & Medical Devel. | 38.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.12%